Objective We evaluated the short-term effects of smoking cessation therapy with varenicline on the lung function. Methods In this study, 81 subjects received 12 weeks of smoking cessation therapy with varenicline. No changes were made to any previously prescribed medications. A physical examination, blood sampling, and spirometry were performed at the first and last visit. Spirometric lung ages were calculated by a formula based on height and the forced expiratory volume in 1 second. The success group comprised 62 subjects who attained 4-week continuous abstinence confirmed by exhaled carbon monoxide testing; whereas the failure group comprised 19 subjects who did not attain this result. However, the number of cigarettes consumed per day was reduced in all subjects of the failure group. Results The spirometric lung ages significantly improved over the 12-week period in the success group (69.8±24.7 vs. 66.9±24.1, p<0.01); however, spirometric lung ages significantly deteriorated in the failure group (70.5±25.5 vs. 73.7±26.9, p<0.01). The effect sizes (Cohen's d) of spirometric lung age in the success and failure groups were 0.37 and 0.81, respectively. The post-hoc statistical power of the spirometric lung age in the success and failure groups was 0.83 and 0.91, respectively. According to a multiple regression analysis, success in smoking cessation exhibited an independent association with the difference in spirometric lung age between the last visit and baseline (p<0.01). Conclusion These findings suggest that successful smoking cessation therapy with varenicline improves the spirometric lung age in the short term.
Introduction
Cigarette smoking is the most important preventable cause of cardiovascular disease (1) . It causes inflammation and oxidative stress and leads to vasomotor dysfunction and altered blood coagulation (2) . Smoking is also the most important risk factor for developing chronic obstructive pulmonary disease (COPD), which is characterized by airflow limitation (3) . Spirometry is used to assess airflow limitation, particularly through the measurement of forced expiratory volume in 1 second (FEV1). A low FEV1 predicts not only an increased rate of decline in FEV1 (4), but also morbidity and mortality from cardiovascular disease (5) . Smoking cessation is the only effective treatment for slowing down an accelerated decline in FEV1 (6, 7) .
The spirometric lung age, calculated with a formula based on height and FEV1, was developed by Morris and Temple as a way of making spirometry data easier to understand and also as a potential psychological tool to confront smokers with an easy-to-understand representation of their deteriorating lungs (8) . Even though there are studies that focused on the effectiveness of telling patients their spirometric lung age to modify detrimental behavior (9, 10) , it remains unclear whether intensive smoking-cessation therapy can affect spirometric lung age in the short term. In addition, it is unknown whether subjects who do not achieve complete cessation can improve their spirometric lung age in 81 study subjects the short term by smoking fewer cigarettes. We therefore evaluated the short-term effects on the spirometric lung age of smoking cessation therapy with varenicline, comparing the results of subjects who succeeded in complete smoking cessation with those of subjects who only reduced the number of cigarettes they smoked per day.
Materials and Methods

Subjects
A total of 203 subjects expressing a desire to quit smoking presented at the Tokyo Kita Medical Center between August 2010 and August 2014. Of these, 140 completed 12 weeks of smoking cessation therapy. All subjects fulfilled the following criteria: (1) aged 20 years or older, (2) Brinkman index (number of cigarettes per day × smoking years) score " 200, (3) Tobacco Dependence Screener score " 5 (11), and (4) stated motivation to immediately quit smoking. These criteria were established by the Japanese medical insurance system for nicotine-dependent outpatients. The exclusion criteria included undergoing an operation, receiving chemotherapy, contracting an infectious disease, or experiencing an injury at any time from 3 months before the first visit to completion of the smoking cessation therapy. Any subjects whose medications were changed within the same 3-month period before or during the study were also excluded to preclude the influence of these changes on spirometry during therapy. In total, 81 subjects who received 12 weeks of smoking cessation therapy with varenicline and who fulfilled the criteria were included in this study. Patient selection is summarized in Figure. Written informed consent was obtained from all subjects, and this study was approved by the ethics committee at the Tokyo Kita Medical Center.
Smoking cessation therapy with varenicline
All subjects were prescribed varenicline titrated up to 1.0 mg twice daily (0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, then 1.0 mg twice daily for 11 weeks). The target smoking cessation date was planned to be 7 days after varenicline initiation. After the first visit on day 1, follow-up visits were scheduled on days 15, 29, 57, and 85. The self-reported smoking status and exhaled carbon monoxide concentrations were assessed at each visit. The criterion for inclusion in the success group was 4 weeks of continuous abstinence during weeks 9 through 12, defined as self-reported abstinence from smoking during this period confirmed by an exhaled carbon monoxide measurement of ! 10 parts per million during the final visit (12) .
Lung function measurement
Spirometry was performed with a dry rolling-seal spirometer using techniques that met the published standards (13) . The spirometric lung ages were calculated using the following equations suitable for Japanese and established by the Japanese Respiratory Society (14):
Spirometric lung age (men) = (0.036× height (cm)-1.178-FEV1 (liter))/0.028.
Spirometric lung age (women) = (0.022× height (cm)-0.005-FEV1 (liter))/0.022.
Blood sampling
Venous blood samples were obtained from all subjects at the first and last visits. All serum samples were analyzed for C-reactive protein (CRP), and the CRP levels were measured within 1 h after sampling.
Statistical analysis
The mean values in the success and failure groups were compared using an unpaired t-test, whereas those for the first (baseline) and last visits in both groups were compared using a paired t-test. The frequencies were compared between the groups using the chi-square test or Fisher's exact test. The CRP levels were analyzed using a log transformation because the distributions of the CRP levels were not Gaussian. Factors that could possibly affect the difference in the spirometric lung age between the last visit and baseline were examined using a univariate regression analysis. Independent predictive parameters for this difference were ascertained by a multivariate logistic regression analysis, including all covariates with a p-value <0.10 in the univariate analysis. All tests were two-tailed, with p<0.05 demarcating statistical significance. Analyses were performed using the PASW Statistics software program version 18.0 (SPSS Inc., Chicago, USA). The G* power 3 program (Erdfelder, Faul, & Buchner, Mannheim, Germany) was used to calculate effect sizes and perform post-hoc power analyses (15) .
Results
Of the 81 study subjects, 62 met the criteria for the success group. Their baseline clinical characteristics are shown in Table 1 . There were no significant differences between the success and failure groups with regard to clinical characteristics, including age, gender, body weight, body mass index, smoking status, lung function, loge-CRP, and use of medication. As shown in Table 2 , all subjects in the failure group reported a reduction in the number of cigarettes smoked per day from the first visit to the last visit. Two subjects in the failure group reported no smoking during the final four weeks of therapy; however, their exhaled carbon monoxide levels were >10 parts per million at the last visit, excluding them from inclusion in the success group.
As shown in Table 3 , the spirometric lung age decreased significantly after smoking cessation therapy in the success group (69.8±24.7 vs. 66.9±24.1, p<0.01). The Loge-CRP levels also decreased significantly after smoking cessation therapy in the success group (−2.77±1.26 vs. −3.08±1.00 mg/dL, p=0.02). The difference between the spirometric lung age and chronological age improved significantly after smoking cessation therapy in the success group (9.6±18.5 vs. 6.7±17.7, p<0.01). The effect sizes (Cohen's d) of the spirometric lung age, loge-CRP levels and the difference between the spirometric lung age and chronological age were meaningful (0.37, 0.36 and 0.38, respectively), and the post- hoc statistical power for spirometric lung age was >0.8 ( Table 3 ).
In the failure group, the spirometric lung age increased significantly after smoking cessation therapy (spirometric lung age: 62.1±20.4 vs. 64.9±21.7 p<0.01) ( Table 4) . The difference between the spirometric lung age and chronological age significantly deteriorated after smoking cessation therapy in the failure group (10.7±21.6 vs. 13.9±22.4, p< 0.01). The effect size of the spirometric lung age in the failure group was high (d = 0.86), and the post-hoc statistical power for the spirometric lung age was >0.8 (Table 4) .
A univariate regression analysis revealed that success in smoking cessation correlated negatively with a difference in the spirometric lung age between the last visit and baseline (p<0.01); no other variables were statistically significant (Table 5) . After including the use of statins, of which the p value was less than 0.10 according to a univariate analysis, a multiple regression analysis showed that success in smoking cessation and the use of statins exhibited independent associations with a decrease in the spirometric lung age between the last visit and baseline (p<0.01 and p=0.04, respectively) ( Table 5) .
Discussion
Several clinical trials of smoking cessation have demonstrated substantial reductions in the risk of cardiovascular events in those who quit smoking (16) (17) (18) . Observational data suggest that smoking cessation reduces the risk for cardiovascular events and that the decline in risk begins within months after quitting (19). Previous studies have reported that a decline in FEV1 normalized 2 years after smoking cessation (20, 21) . To the best of our knowledge, the present study represents the first report demonstrating that successful smoking cessation is significantly associated with an improvement in the lung function in the short term: just 12 weeks after initiating treatment and as few as 4 weeks after achieving complete abstinence from smoking. We previously reported that successful smoking cessation therapy with varenicline increased the serum apolipoprotein A-I levels, which have anti-inflammatory properties (22) . However, the precise mechanisms by which smoking cessation leads to an improved spirometric lung age are unclear. One possible explanation for this phenomenon is that resolving the inflammation induced by cigarette smoking may contribute to an improvement in the lung function and a reduction in the CRP levels, as observed in the success group. Further, the present study demonstrated in a multiple regression analysis that the use of statins exhibited an independent association with the decrease in spirometric lung age between the last visit and baseline. Previous studies have shown that statins have anti-inflammatory effects (23, 24) , and statins have been reported to be associated in observational studies of COPD with reductions in the rate and severity of exacerbations, the rate of hospitalizations, and mortality (25) (26) (27) . Although simvastatin did not show a therapeutic benefit in patients with moderate to severe COPD in a randomized trial (28) , these findings suggest that resolving the inflammation induced by cigarette smoking may contribute to an improvement in the lung function.
Another notable finding of our study was that reducing the number of cigarettes smoked per day did not lead to any significant short-term improvements in the lung function. Indeed, failure to achieve complete abstinence from smoking after the smoking cessation therapy with varenicline resulted in a deterioration of the spirometric lung age in the short term. Even though the number of subjects in the failure group was small, the effect sizes and post hoc power of spirometric lung age and FEV1 were significantly and meaningfully high. These findings agree with those of previous reports showing a considerable decline in lung function in smokers (7, 29) , but it is unclear whether varenicline directly precipitated the decline of lung function in the present study. A low FEV1 predicts morbidity and mortality from cardiovascular disease (5) , and simply reducing the number of cigarettes smoked per day appears to be insufficient to achieve an improvement in the lung function and a reduction in the risk for cardiovascular events.
There are several limitations associated with our study. First, this study was conducted at only one hospital and was limited by the small number of subjects, particularly in the failure group. We did not have a sufficient number of study subjects to stratify each group (i.e. by duration of smoking cessation in the success group). Second, the criteria for successful smoking cessation were mainly dependent upon the subjects' self-reports of their behavior; therefore, it is possible that subjects who did not exactly fulfill the success criteria were treated as part of the success group. Third, because this study was performed at an outpatient clinic, we could not assess the role of environmental confounders, such as jobs or place of residence, on the lung function. Further studies involving a larger sample size and multiple centers and including consideration of the effect of potential confounders should help to elucidate the precise effects of smoking cessation on the lung function.
Conclusion
Our findings suggest that successful smoking cessation therapy with varenicline improves the spirometric lung age in the short term. Simply reducing the number of cigarettes smoked per day therefore appears to be insufficient to achieve an improvement in the lung function.
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